Genexine제넥신
095700 · KOSDAQ · ₩095700 · 제넥신
₩2,165▼ ₩85 (3.78%)End-of-day · Oct 29, 2026 · End-of-day prices.
Filings
- Rights offering (paid-in capital increase) decision기타주요경영사항 (유상증자결정(제3자배정-소액공모) 철회)Oct 26, 2026Open on DART
High impactPredicted impact: High
Rights offering decision; new shares may be large, and the company's revenue is tiny versus its market value.
- Small Public Offering Performance Report소액공모실적보고서Oct 26, 2026Open on DART
Predicted impact: Low
Small public offering report; earlier rights offering decisions already disclosed, and size is small.
- [Amended] Small-Scale Public Offering Disclosure Documents (Equity Securities)[기재정정]소액공모공시서류(지분증권)Oct 26, 2026Open on DART
Predicted impact: Low
- Amended: Rights offering (paid-in capital increase) decision[기재정정]주요사항보고서(유상증자결정)Oct 26, 2026Open on DART
Predicted impact: Low
- Small-Scale Public Offering Disclosure Documents (Equity Securities)소액공모공시서류(지분증권)Oct 16, 2026Open on DART
Predicted impact: Medium
Small public offering filing for equity follows the rights offering decision already reported; size not given.
- Rights offering (paid-in capital increase) decision주요사항보고서(유상증자결정)Oct 16, 2026Open on DART
High impactPredicted impact: High· Actual: −9.9% vs sector, volume 0.4× normal (5 trading days)
Rights offering decision; new shares may be large, and the company's revenue is tiny versus its market value.
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Oct 6, 2026Open on DART
- Shareholders' meeting called주주총회소집결의 (임시주주총회)Oct 6, 2026Open on DART
- Notice on Grant of Stock Purchase Options주식매수선택권부여에관한신고Aug 24, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (GXI7 관련 마일스톤 기술료 청구)Aug 21, 2026Open on DART
- Half-year report (Jun 2026)반기보고서 (2026.06)Aug 13, 2026Open on DART
- Decision to Provide Collateral for Third Party타인에대한담보제공결정Jul 3, 2026Open on DART
- [Amended] Decision on Provision of Collateral for Third Parties[기재정정]타인에대한담보제공결정Jul 3, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (에페사프리필드시린지주(GX-E4) 한국 품목허가 신청결과)Jun 4, 2026Open on DART
- Quarterly report (Mar 2026)분기보고서 (2026.03)May 14, 2026Open on DART
- Decision to Provide Collateral for Third Party타인에대한담보제공결정May 6, 2026Open on DART
- Lawsuit filed or ruled소송등의판결ㆍ결정(일정금액이상의청구)Apr 15, 2026Open on DART
- Annual general meeting results정기주주총회결과Mar 30, 2026Open on DART
- Notice of Reason for Concentrated Shareholders' Meeting Date주주총회집중일개최사유신고Mar 11, 2026Open on DART
- Shareholders' meeting called주주총회소집결의Mar 11, 2026Open on DART
- Reference Document for Proxy Solicitation of Voting Rights의결권대리행사권유참고서류Mar 11, 2026Open on DART
- Notice of shareholders' meeting주주총회소집공고Mar 11, 2026Open on DART
- Notice on Grant of Stock Purchase Options주식매수선택권부여에관한신고Mar 11, 2026Open on DART
- Annual report (Dec 2025)사업보고서 (2025.12)Mar 11, 2026Open on DART
- Audit report submitted감사보고서제출Mar 10, 2026Open on DART
- Change in Revenue or Profit/Loss Structure of 30% or More (15% or More for Large Companies)매출액또는손익구조30%(대규모법인은15%)이상변동Feb 2, 2026Open on DART
- [Corrected] New Facility Investment, etc.[기재정정]신규시설투자등Jan 7, 2026Open on DART
- Other Market Notice (Special Treatment for Revenue of R&D Excellence Companies)기타시장안내 (연구개발 우수기업 매출액 특례적용 관련)Jan 6, 2026Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 12, 2025Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험결과) (건강한 자원자 코카시안 및 아시아인에서 efepoetin alfa 단회 정맥 투여 후 약동/약력학적 특성, 안전성 및 내약성을 평가하기 위한(GXE4) 1상 임상시험 결과보고서(CSR) 수령)Dec 9, 2025Open on DART
- Quarterly report (Sep 2025)분기보고서 (2025.09)Nov 13, 2025Open on DART
- Amended: Lawsuit filed or ruled[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)Nov 7, 2025Open on DART
- Securities Issuance Results (Voluntary Disclosure)증권발행결과(자율공시)Oct 1, 2025Open on DART
- Amended: Convertible bond issue decision[기재정정]주요사항보고서(전환사채권발행결정)Sep 24, 2025Open on DART
- Convertible bond issue decision주요사항보고서(전환사채권발행결정)Sep 24, 2025Open on DART
- Notice on Grant of Stock Purchase Options주식매수선택권부여에관한신고Sep 23, 2025Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (GXI7 관련 마일스톤 기술료 청구)Aug 20, 2025Open on DART
- Half-year report (Jun 2025)반기보고서 (2025.06)Aug 14, 2025Open on DART
- Quarterly report (Mar 2025)분기보고서 (2025.03)May 14, 2025Open on DART
- Change of CEO대표이사변경Mar 26, 2025Open on DART
- Annual general meeting results정기주주총회결과Mar 26, 2025Open on DART
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 26, 2025Open on DART
- Notice on Grant of Stock Purchase Options주식매수선택권부여에관한신고Mar 26, 2025Open on DART
- Audit report submitted감사보고서제출Mar 10, 2025Open on DART
- Shareholders' meeting called주주총회소집결의Mar 10, 2025Open on DART
- Annual report (Dec 2024)사업보고서 (2024.12)Mar 10, 2025Open on DART
- Reference Document for Proxy Solicitation of Voting Rights의결권대리행사권유참고서류Mar 10, 2025Open on DART
- Notice of shareholders' meeting주주총회소집공고Mar 10, 2025Open on DART
- Notice on Grant of Stock Purchase Options주식매수선택권부여에관한신고Mar 10, 2025Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험결과) (재발성 교모세포종 환자에서 베바시주맙 (bevacizumab)과 GX-I7 병용투여의 유효성 및 안전성을 확인하기 위한 공개형, 단일군 제2상 임상시험 결과)Feb 26, 2025Open on DART
Titles in Korean until English translations are added.
Also known as: Genexine / 제넥신 / 095700 / KRX:095700
Source: KRX statistical information